• Boehringer Ingelheim and OSE
Immunotherapeutics enter into a global license and collaboration
agreement in immuno-oncology to develop OSE-172, a novel checkpoint
inhibitor antibody targeting myeloid lineage cells
• Assuming all milestones are met, OSE stands to receive more than €1.1 billion
•
OSE-172, an anti-SIRP-alpha monoclonal antibody, is currently in late
stage preclinical development with potential in various cancers
•
With this collaboration, Boehringer Ingelheim strengthens a core pillar
of its cancer immunology and immune modulation strategy focusing on
novel approaches to treat cancer
INGELHEIM, Germany & NANTES, France-Thursday, April 5th 2018 [ AETOS Wire ]
(BUSINESS WIRE)
-- Boehringer Ingelheim and OSE Immunotherapeutics, a biotechnology
company focused on the development of innovative immunotherapies, today
announced a collaboration and exclusive worldwide collaboration and
license agreement to jointly develop OSE-172, a SIRP-alpha antagonist
targeting myeloid lineage cells.
SIRP-alpha is
a receptor expressed by myeloid lineage cells such as Dendritic Cells
(DCs), tumor-associated macrophages (TAMs) and Myeloid-Derived
Suppressor Cells (MDSCs). In targeting SIRP- alpha, OSE-172 prevents the
ligand CD47 from binding to and triggering the cellular inhibitory
effects of SIRP-alpha. OSE-172 has the potential to enhance anti-tumor
immunity by improving T cell activity through enhancement of DC antigen
presentation functionality, potentiating the phagocytic and inflammatory
properties of macrophages in the tumor microenvironment and enabling
differentiation of MDSCs to an effector state.
“This
partnership with Boehringer Ingelheim is a real recognition of the value
of our innovative approach to treating cancer and will create an
exciting new alliance to fuel the phase 1 development of OSE-172,” said
Dr. Dominique Costantini, CEO of OSE Immunotherapeutics. “Boehringer
Ingelheim’s expertise and insights will be invaluable as we step up the
clinical development and work to commercialize this new treatment
paradigm.”
“We are
excited to partner with OSE Immunotherapeutics to develop this
promising, novel cancer immunotherapy,” said Jonathon Sedgwick, Ph.D.,
Global Head Cancer Immunology & Immune Modulation Research at
Boehringer Ingelheim. “A key area of focus is the identification of
drugs that target myeloid cell immune regulatory receptors of which
SIRP-alpha is a leading example. We are dedicated to developing
ground-breaking, first-in-class therapies that can transform the lives
of patients and help win the fight against cancer.”
Boehringer
Ingelheim has acquired the global rights to develop, register and
commercialize OSE-172, a monoclonal antibody targeting SIRP-alpha which
is expressed in myeloid lineage cells, as part of their continued
commitment to research and innovation in immuno-oncology. Under the
terms of the agreement, OSE Immunotherapeutics will receive a €15
million upfront payment from Boehringer Ingelheim, and potential
additional short-term milestones of up to €15 million upon initiation of
a phase 1 clinical study. OSE Immunotherapeutics stands to receive more
than €1.1 billion upon reaching pre-specified development,
commercialization and sales milestones, plus royalties on worldwide net
sales.
Please click on the link for ‘Notes to Editors’: http://www.boehringer-ingelheim.com/New-Partnership-to-develop-novel-checkpoint-inhibitor
Contacts
Media Contacts:
Boehringer Ingelheim
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-90815
reinhard.malin@boehringer-ingelheim.com
or
Linda Ruckel
Associate Director, Media and Corporate Reputation
Boehringer Ingelheim U.S.
Media + PR
P: + 203-791-6672
linda.ruckel@boehringer-ingelheim.com
or
OSE Immunotherapeutics
Alexis Peyroles, COO
P: +33 611 511 977
alexis.peyroles@ose-immuno.com
or
Florence Portejoie
French Media: FP2COM
P: +33 607 768 283
fportejoie@fp2com.fr
or
Linda Dyson, MPH
U.S. Media: LifeSci Public Relations
P: +1 973.986.5973
linda@lifescipublicrelations.com
No comments:
Post a Comment